Unjha Formulations Ltd

Unjha Formulations Ltd’s share price declined sharply on 17 Jun 2026, hitting a new 52-week low of Rs 17.55. This marks a significant drop for the pharmaceutical company amid a challenging market environment and deteriorating financial metrics.

Unjha Formulations Ltd has been downgraded from a Sell to a Strong Sell rating as of 1 June 2026, reflecting deteriorating technical indicators and persistent financial weaknesses. Despite a very attractive valuation, the company’s flat quarterly performance, operating losses, and bearish technical trends have compelled analysts to revise their outlook, signalling caution for investors in this pharmaceuticals micro-cap.

Unjha Formulations Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 25 May 2026, driven primarily by a shift in technical indicators despite ongoing challenges in financial performance and valuation metrics. This nuanced change reflects a complex interplay of quality, valuation, financial trends, and technical signals that investors should carefully consider.

Unjha Formulations Ltd., a Gujarat-based pharmaceutical company specialising in Isabgol (Psyllium) formulations, reported a troubling quarterly performance for Q4 FY26, posting a net loss of ₹0.74 crores despite revenue growth. The micro-cap company, with a market capitalisation of ₹9.00 crores, saw its stock decline 0.55% to ₹20.00 following the results announcement, reflecting investor concerns about deteriorating profitability and operational challenges that have plagued the company throughout the fiscal year.

Unjha Formulations Ltd has been downgraded from a Sell to a Strong Sell rating as of 7 May 2026, reflecting deteriorating technical indicators and underwhelming financial performance. The company’s micro-cap status, combined with a sharp decline in share price and weak debt servicing ability, has prompted a reassessment of its investment appeal across quality, valuation, financial trend, and technical parameters.

Unjha Formulations Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 29 April 2026, driven primarily by a shift in technical indicators despite persistent fundamental challenges. The micro-cap pharmaceutical company’s Mojo Score has improved to 31.0, reflecting a nuanced change in market sentiment and technical trends, even as financial performance remains flat and long-term fundamentals show weaknesses.

Unjha Formulations Ltd’s stock price declined sharply on 7 April 2026, hitting a new 52-week low of Rs.18.6. This marks a significant downturn for the pharmaceutical and biotechnology company, reflecting ongoing challenges in its market performance and valuation metrics.

Unjha Formulations Ltd’s stock price declined to a fresh 52-week low of Rs.18.99 on 2 April 2026, marking a significant drop amid broader market weakness and sectoral pressures. The stock has been underperforming, reflecting a combination of company-specific factors and challenging market conditions.

A sharp decline of 9.31% today dragged Unjha Formulations Ltd to a fresh 52-week low of Rs 19, marking a significant underperformance against both its sector and the broader market. This drop comes amid a broader market sell-off, yet the stock’s fall notably outpaces the sector’s 3.63% decline and the Sensex’s 2.46% fall, highlighting company-specific pressures.

Unjha Formulations Ltd’s shares declined to a fresh 52-week low of Rs.19.15 today, marking a significant milestone in the stock’s ongoing downward trajectory. The pharmaceutical company’s stock has underperformed both its sector and broader market indices, reflecting persistent concerns over its financial metrics and market positioning.

Unjha Formulations Ltd, a player in the Pharmaceuticals & Biotechnology sector, has reported a flat financial performance for the quarter ended December 2025, signalling a notable shift from its previously positive growth trajectory. Despite a modest increase in profit after tax (PAT) over the last six months, the company’s overall financial trend score has deteriorated sharply, prompting a downgrade in its Mojo Grade to Strong Sell.

Unjha Formulations Ltd., a Gujarat-based pharmaceutical company specialising in Ayurvedic and Isabgol (Psyllium) formulations, reported a concerning quarter in Q3 FY26, with net profit plummeting 70.73% quarter-on-quarter to ₹0.24 crores from ₹0.82 crores in Q2 FY26. Despite modest revenue growth of 2.80% QoQ, the company's profitability came under severe pressure from margin compression.

Unjha Formulations Ltd has seen its investment rating upgraded from Sell to Hold as of 29 December 2025, reflecting a nuanced improvement across technical indicators, valuation metrics, and recent financial performance. Despite lingering challenges in long-term fundamentals and market underperformance, the company’s evolving technical trend and attractive valuation have prompted a reassessment of its outlook within the Pharmaceuticals & Biotechnology sector.

Unjha Formulations Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 23 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 24 December 2025, providing investors with the most up-to-date view of the company’s fundamentals, returns, and market performance.